Coccidiosis is a disease caused by the development of parasites of the genus Eimeria, coccidia, in the intestinal mucosa of chickens, which can cause various health impacts ranging from reduced performance to significant mortality. Current methods of prevention are the addition of anticoccidial molecules in feed or vaccination in the hatchery. The objective of the study is to find alternatives that are as efficient from a technical as they are economical point of view. For this, three types of products were tested as supplementation in feed, compared to vaccination in the hatchery, under challenged conditions, at the experimental station in Benquet (40). Thus, 1440 one-day-old male broiler chickens of the JA757NK strain were separated into 6 treatments, repeated 6 times, in 36 hutches, ie 240 animals per treatment. The chickens of the first five treatments were inoculated on D15 with coccidia: a negative control, “T-” (without supplementation), three supplemented treatments (product A, B, C) and a vaccinated treatment, “vaccine” (Paracox 5 ). The positive control, “T+” was not inoculated and did not receive supplementation. The chickens had access to an outdoor run from 42 days. Throughout breeding (D0-78), zootechnical performances (weight, consumption, mortality) were recorded by parquet. On D21, the Reid & Johnson lesion scores were performed on 4 chickens/pen, ie 24 chickens per treatment. At 77 days, no significant difference in weight was noted between the groups (on average 2.491 kg, p=0.493). The intestinal lesions of the vaccinated group are significantly lower than those of the other treatments (E. acervulina Vaccine 2.2 Other 2.9; E. tenella Vaccine 1.9 Other 2.5, p < 0.0001). Concerning the alternative solutions, the results are in favor of the use of product C because it made it possible to support the performance of chickens during the critical period linked to coccidiosis (D0-28), by achieving similar performance to vaccinated animals and by obtaining performance superior to T- (GMQ D0-28 T-: 17.9 g/d, Product C: 18.6 g/d, Vaccine: 18.7 g/d, p =0.034; Live Weight D28 T-: 539 g, Product C: 559 g, Vaccine: 561 g, p=0.041). In addition, this solution is economically neutral for producers. However, this product, like the others tested, had no effect on reducing lesions.
–
